1. Generics Bulletin
  2. >>Products

‘Rapid Adoption’ Expected For US Humira Biosimilars

AmerisourceBergen’s McGowan Also Sees Oncology Biosimilars Capturing Record Market Share

 
• By Dave Wallace

Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.

Amerisource_Bergen
AmerisourceBergen’s Sean McGowan marks major milestones for biosimilars • Source: Shutterstock

The past year has seen significant progress for US biosimilars, AmerisourceBergen’s senior director of biosimilars, Sean McGowan, tells Generics Bulletin in an exclusive Q&A. With oncology products set to capture record market share and the first US Food and Drug Administration approvals for interchangeable and ophthalmic biosimilars, McGowan also suggests that uptake will be fast once biosimilar challengers to Humira (adalimumab) hit the market from 2023.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Jazz has agreed a nine figure settlement agreement in the US with purchasers of its Xyrem blockbuster following claims that it illegally delayed generic competition to the blockbuster treatment for narcolepsy via patent-litigation settlement agreements with several ANDA sponsors.

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab

 
• By Dave Wallace

Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.